Drug Profile
Insulin inhalation - Nektar Therapeutics
Alternative Names: Exubera; HMR 4006Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Nektar Therapeutics
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Market Withdrawal Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 21 Oct 2008 Novartis agrees to acquire certain areas of pulmonary business from Nektar
- 11 Apr 2008 Nektar Therapeutics terminates all negotiations with potential marketing and development partners for its inhaled insulin programmes
- 09 Apr 2008 Discontinued - Registered for Type-1 diabetes mellitus in European Union (Inhalation)